Nikolay Runev
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Nikolay Runev has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Emil Manov
Department of Internal Diseases “Prof. St. Kirkovich”, Medical University of Sofia, 1431 Sofia, Bulgaria
14 shared publications - Stefan Naydenov
Department of Internal Diseases “Prof. St. Kirkovich”, Medical University of Sofia, 1431 Sofia, Bulgaria
12 shared publications - Andrey Ivanov
Department of Propaedeutics of Internal Diseases "Prof. St. Kirkovich", Medical University, Sofia, Bulgaria
2 shared publications - Margarita Jekova
Department of Internal Diseases “Prof. St. Kirkovich”, Medical University of Sofia, 1431 Sofia, Bulgaria
2 shared publications - Nadya Naydenova
Univ Hosp St Ekaterina, Cardiol Clin, 52A,P Slaveykov Blvd, Sofia 1431, Bulgaria
2 shared publications Temenuga Ivanova Donova
2 shared publications
Latest Publications
- 2 April 2026
- Published by Peytchinski Publishing Ltd. in Journal of IMAB – Annual Proceeding (Scientific Papers)
- Vol. 32 (2) , 6779-6791
LEFT VENTRICULAR HYPERTROPHY: MECHANISM OF DEVELOPMENT
Left ventricular hypertrophy (LVH) is an enlargement of the left ventricle caused by chronically increased hemodynamic load, such as arterial hypertension or aortic stenosis. In the initial stages, LVH has a protective nature, but later it can lead to heart failure and arrhythmias. The biochemical mechanisms of hypertrophy involve complex molecular pathways regulating cell proliferation and protein synthesis. These pathways interact through cell surface receptors, transcription factors, and enzymes, leading to structural and functional changes in cardiomyocytes. Changes in the extracellular matrix, inflammatory processes, and oxidative stress play an important role in the transition of hypertrophy from adaptive to pathological stage. Various hormones, vasoactive substances, growth factors, and cytokines are involved in myocardial hypertrophy. Despite significant knowledge concerning signaling pathways related to receptor stimulation, little is still known about the mechanochemical systems that transduce physical signals into cellular responses.
- 2 April 2026
- Published by Peytchinski Publishing Ltd. in Journal of IMAB – Annual Proceeding (Scientific Papers)
- Vol. 32 (2) , 6779-6791
LEFT VENTRICULAR HYPERTROPHY: MECHANISM OF DEVELOPMENT
Left ventricular hypertrophy (LVH) is an enlargement of the left ventricle caused by chronically increased hemodynamic load, such as arterial hypertension or aortic stenosis. In the initial stages, LVH has a protective nature, but later it can lead to heart failure and arrhythmias. The biochemical mechanisms of hypertrophy involve complex molecular pathways regulating cell proliferation and protein synthesis. These pathways interact through cell surface receptors, transcription factors, and enzymes, leading to structural and functional changes in cardiomyocytes. Changes in the extracellular matrix, inflammatory processes, and oxidative stress play an important role in the transition of hypertrophy from adaptive to pathological stage. Various hormones, vasoactive substances, growth factors, and cytokines are involved in myocardial hypertrophy. Despite significant knowledge concerning signaling pathways related to receptor stimulation, little is still known about the mechanochemical systems that transduce physical signals into cellular responses.
- 26 January 2026
- Published by Peytchinski Publishing Ltd. in Journal of IMAB – Annual Proceeding (Scientific Papers)
- Vol. 32 (1) , 6708-6718
ARTERIAL HYPERTENSION: LEFT VENTRICULAR GEOMETRY AND DIASTOLIC DYSFUNCTION
Echocardiography is an established method for assessing left ventricular structure and function in patients with arterial hypertension (AH). Purpose. The study aims to investigate left ventricular geometry and diastolic dysfunction in patients with arterial hypertension and to assess gender-related differences in the established data. Material/methods. A total of 278 individuals were studied, including 30 healthy controls (16 women and 14 men) and 248 patients with arterial hypertension (139 women and 109 men). The echocardiographic examination included M-Mode and B-Mode echocardiography, pulsed-wave spectral Doppler, and pulsed-wave tissue Doppler imaging. Results. Using the criteria of left ventricular mass index (LVMI) > 115 g/m2 in men and LVMI > 95 g/m2 in women for defining left ventricular hypertrophy (LVH), we found LVH in 147 of the hypertensive patients (59.27%). In our patients, LVH was more common in women. LVH was found in 97 women (69.78% of the women with AH) and 50 men (45.87% of the men with AH). One hundred and six (106) patients (42.74%) had no diastolic dysfunction. Grade 1 diastolic dysfunction was found in 95 patients (38.31%), grade 2 in 43 patients (17.34%), and grade 3 in 4 patients (1.61%). Conclusion. In the studied patients with arterial hypertension, a number of echocardiographic indices were found which differed significantly from those in the individuals from the control group. Regular echocardiographic assessment is essential for guiding therapy and reducing the risk in these patients.
- 26 January 2026
- Published by Peytchinski Publishing Ltd. in Journal of IMAB – Annual Proceeding (Scientific Papers)
- Vol. 32 (1) , 6708-6718
ARTERIAL HYPERTENSION: LEFT VENTRICULAR GEOMETRY AND DIASTOLIC DYSFUNCTION
Echocardiography is an established method for assessing left ventricular structure and function in patients with arterial hypertension (AH). Purpose. The study aims to investigate left ventricular geometry and diastolic dysfunction in patients with arterial hypertension and to assess gender-related differences in the established data. Material/methods. A total of 278 individuals were studied, including 30 healthy controls (16 women and 14 men) and 248 patients with arterial hypertension (139 women and 109 men). The echocardiographic examination included M-Mode and B-Mode echocardiography, pulsed-wave spectral Doppler, and pulsed-wave tissue Doppler imaging. Results. Using the criteria of left ventricular mass index (LVMI) > 115 g/m2 in men and LVMI > 95 g/m2 in women for defining left ventricular hypertrophy (LVH), we found LVH in 147 of the hypertensive patients (59.27%). In our patients, LVH was more common in women. LVH was found in 97 women (69.78% of the women with AH) and 50 men (45.87% of the men with AH). One hundred and six (106) patients (42.74%) had no diastolic dysfunction. Grade 1 diastolic dysfunction was found in 95 patients (38.31%), grade 2 in 43 patients (17.34%), and grade 3 in 4 patients (1.61%). Conclusion. In the studied patients with arterial hypertension, a number of echocardiographic indices were found which differed significantly from those in the individuals from the control group. Regular echocardiographic assessment is essential for guiding therapy and reducing the risk in these patients.
- Open Access
- 14 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (4) , 1268
Could Renal Vascular Variations Be Associated with Resistant Hypertension? A Single-Center Study
Background: Anatomical variations in renal vessels are common in humans. However, the clinical significance of these congenital vascular abnormalities remains incompletely understood. This study aimed to assess the prevalence and characteristics of renal vascular variants in patients with arterial hypertension (HTN) and their association with the development of resistant HTN. Methods: We screened 3762 consecutive hypertensive patients hospitalized in our clinic and identified 128 (3.4%) with resistant HTN. These patients were matched with 128 hospitalized patients with controlled HTN. All participants underwent contrast-enhanced computed tomography imaging of the kidneys, including renovasography. Results: Anatomical renal vascular variations were identified in 64 (25%) of the 256 participants: 49 (38.3%) of the 128 patients with resistant HTN and 15 (11.7%) of the 128 patients with controlled HTN (p < 0.001). Among patients with renal vascular abnormalities, 76.6% had resistant HTN, while 23.4% had controlled HTN (p < 0.001). A regression analysis demonstrated a strong association between the presence of renal vascular variants and the development of resistant HTN, with an odds ratio of 4.67. Conclusions: Anatomical renal vascular variations were found to be common among hypertensive patients in this study and were strongly associated with the development of treatment-resistant HTN.
- 14 February 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (4) , 1268
Open AccessCould Renal Vascular Variations Be Associated with Resistant Hypertension? A Single-Center Study
Background: Anatomical variations in renal vessels are common in humans. However, the clinical significance of these congenital vascular abnormalities remains incompletely understood. This study aimed to assess the prevalence and characteristics of renal vascular variants in patients with arterial hypertension (HTN) and their association with the development of resistant HTN. Methods: We screened 3762 consecutive hypertensive patients hospitalized in our clinic and identified 128 (3.4%) with resistant HTN. These patients were matched with 128 hospitalized patients with controlled HTN. All participants underwent contrast-enhanced computed tomography imaging of the kidneys, including renovasography. Results: Anatomical renal vascular variations were identified in 64 (25%) of the 256 participants: 49 (38.3%) of the 128 patients with resistant HTN and 15 (11.7%) of the 128 patients with controlled HTN (p < 0.001). Among patients with renal vascular abnormalities, 76.6% had resistant HTN, while 23.4% had controlled HTN (p < 0.001). A regression analysis demonstrated a strong association between the presence of renal vascular variants and the development of resistant HTN, with an odds ratio of 4.67. Conclusions: Anatomical renal vascular variations were found to be common among hypertensive patients in this study and were strongly associated with the development of treatment-resistant HTN.
- Open Access
- 25 December 2024
- Published by MDPI AG in Preprints.org
Could Renal Vascular Variations Be Associated with Resistant Hypertension: A Single-Center Study
Background: Anatomical variations in renal vessels are common in humans. However, the clinical significance of these congenital vascular abnormalities remains incompletely understood. This study aimed to assess the prevalence and characteristics of renal vascular variants in patients with arterial hypertension (HTN) and their association with the development of resistant HTN. Methods: We screened 3,762 consecutive hypertensive patients hospitalized in our clinic and identified 128 (3.4%) with resistant HTN. These patients were matched with 128 hospitalized patients with controlled HTN. All participants underwent contrast-enhanced computed tomography imaging of the kidneys, including renovasography. Results: Anatomical renal vascular variations were identified in 64 (25%) of the 256 participants: 49 (38.3%) of the 128 patients with resistant HTN and 15 (11.7%) of the 128 patients with controlled HTN (p < 0.001). Among patients with renal vascular abnormalities, 76.6% had resistant HTN, while 23.4% had controlled HTN (p < 0.001). Regression analysis demonstrated a strong association between the presence of renal vascular variants and the development of resistant HTN, with an odds ratio of 4.67. Conclusions: Anatomical renal vascular variations were found to be common among hypertensive patients in this study and were strongly associated with the development of treatmentresistant HTN.
- 25 December 2024
- Published by MDPI AG in Preprints.org
Open AccessCould Renal Vascular Variations Be Associated with Resistant Hypertension: A Single-Center Study
Background: Anatomical variations in renal vessels are common in humans. However, the clinical significance of these congenital vascular abnormalities remains incompletely understood. This study aimed to assess the prevalence and characteristics of renal vascular variants in patients with arterial hypertension (HTN) and their association with the development of resistant HTN. Methods: We screened 3,762 consecutive hypertensive patients hospitalized in our clinic and identified 128 (3.4%) with resistant HTN. These patients were matched with 128 hospitalized patients with controlled HTN. All participants underwent contrast-enhanced computed tomography imaging of the kidneys, including renovasography. Results: Anatomical renal vascular variations were identified in 64 (25%) of the 256 participants: 49 (38.3%) of the 128 patients with resistant HTN and 15 (11.7%) of the 128 patients with controlled HTN (p < 0.001). Among patients with renal vascular abnormalities, 76.6% had resistant HTN, while 23.4% had controlled HTN (p < 0.001). Regression analysis demonstrated a strong association between the presence of renal vascular variants and the development of resistant HTN, with an odds ratio of 4.67. Conclusions: Anatomical renal vascular variations were found to be common among hypertensive patients in this study and were strongly associated with the development of treatmentresistant HTN.
- Open Access
- 5 September 2024
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 11 (9) , 279
Prevalence, Clinical Characteristics, and Treatment of Patients with Resistant Hypertension: A Single-Center Study
Background: Resistant hypertension (HTN) is associated with a high risk of cardiovascular complications. Our study aimed to assess the prevalence, characteristics, and treatment of patients with resistant HTN. Methods: We screened 4340 consecutive cardiovascular patients hospitalized in our clinic and identified 3762 with HTN. Of them, 128 fulfilled criteria for resistant HTN and were included in our study. We matched these patients to 128 hospitalized patients with controlled HTN. Results: Resistant HTN patients comprised 3.4% of all hypertensive individuals. Most of these patients (67.2%) were at high or very high cardiovascular risk compared to controlled HTN patients (40.6%); p < 0001. Resistant HTN patients more commonly had concomitant chronic kidney disease (CKD) (60.9%), overweight/obesity (52.3%), dyslipidemias (35.2%), smoking (27.3%), and diabetes (21.9%) compared to controlled HTN patients (37.5%, 29.7%, 28.1%, 14.1%, and 7.8%, respectively); p < 0.001. Regression analysis showed the strongest association of resistant HTN with CKD (OR 6.64), stage III HTN (OR 3.07), and obesity/overweight (OR 2.60). In contrast, single-pill combinations (SPCs) were associated with a lower likelihood of uncontrolled HTN (OR 0.58). Conclusions: Resistant HTN represented a small proportion of all hypertensives in our study, but it was characterized by high/very high cardiovascular risk. Optimized therapy including increased use of SPCs could improve blood pressure control and long-term prognosis for these patients.
- 5 September 2024
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 11 (9) , 279
Open AccessPrevalence, Clinical Characteristics, and Treatment of Patients with Resistant Hypertension: A Single-Center Study
Background: Resistant hypertension (HTN) is associated with a high risk of cardiovascular complications. Our study aimed to assess the prevalence, characteristics, and treatment of patients with resistant HTN. Methods: We screened 4340 consecutive cardiovascular patients hospitalized in our clinic and identified 3762 with HTN. Of them, 128 fulfilled criteria for resistant HTN and were included in our study. We matched these patients to 128 hospitalized patients with controlled HTN. Results: Resistant HTN patients comprised 3.4% of all hypertensive individuals. Most of these patients (67.2%) were at high or very high cardiovascular risk compared to controlled HTN patients (40.6%); p < 0001. Resistant HTN patients more commonly had concomitant chronic kidney disease (CKD) (60.9%), overweight/obesity (52.3%), dyslipidemias (35.2%), smoking (27.3%), and diabetes (21.9%) compared to controlled HTN patients (37.5%, 29.7%, 28.1%, 14.1%, and 7.8%, respectively); p < 0.001. Regression analysis showed the strongest association of resistant HTN with CKD (OR 6.64), stage III HTN (OR 3.07), and obesity/overweight (OR 2.60). In contrast, single-pill combinations (SPCs) were associated with a lower likelihood of uncontrolled HTN (OR 0.58). Conclusions: Resistant HTN represented a small proportion of all hypertensives in our study, but it was characterized by high/very high cardiovascular risk. Optimized therapy including increased use of SPCs could improve blood pressure control and long-term prognosis for these patients.
- Open Access
- 23 July 2024
- Published by MDPI AG in Preprints.org
Prevalence, Clinical Characteristics and Treatment of Patients with Resistant Hypertension: A Single-Center Study
Background: Resistant hypertension (HTN) is associated with high risk of cardiovascular complications. Our study aimed to assess prevalence, characteristics and treatment of patients with resistant HTN; Methods: We screened 4340 consecutive cardiovascular patients and identified 3762 with HTN. Of them 128 fulfilled criteria for resistant HTN and were included in our study. We matched these patients to 128 hypertensive patients with controlled HTN; Results: Resistant HTN patients were 3.4% of all hypertensives. Most of these patients (67.2%) were at high or very high cardiovascular risk compared to controlled HTN patients (40.6%), p<0001. Resistant HTN patients had more frequently concomitant chronic kidney disease (CKD) (60.9%), overweight/obesity (52.3%), dyslipidemias (35.2%), smoking (27.3%) and diabetes (21.9%) compared to controlled HTN patients (37.5%, 29.7%, 28.1%, 14.1% and 7.8% respectively), p<0.001. Regression analysis showed strongest association of resistant HTN with CKD (OR 6.64), stage III HTN (OR 3.07) and obesity/overweight (OR 2.60). In contrast, single-pill combinations (SPCs) were associated with lower likelihood of uncontrolled HTN (OR 0.58); Conclusions: Resistant HTN represented a small proportion of all hypertensives in our study, but it was characterized by high/very high cardiovascular risk. Optimized therapy including increased usage of SPCs could improve blood pressure control and long-term prognosis of these patients.
- 23 July 2024
- Published by MDPI AG in Preprints.org
Open AccessPrevalence, Clinical Characteristics and Treatment of Patients with Resistant Hypertension: A Single-Center Study
Background: Resistant hypertension (HTN) is associated with high risk of cardiovascular complications. Our study aimed to assess prevalence, characteristics and treatment of patients with resistant HTN; Methods: We screened 4340 consecutive cardiovascular patients and identified 3762 with HTN. Of them 128 fulfilled criteria for resistant HTN and were included in our study. We matched these patients to 128 hypertensive patients with controlled HTN; Results: Resistant HTN patients were 3.4% of all hypertensives. Most of these patients (67.2%) were at high or very high cardiovascular risk compared to controlled HTN patients (40.6%), p<0001. Resistant HTN patients had more frequently concomitant chronic kidney disease (CKD) (60.9%), overweight/obesity (52.3%), dyslipidemias (35.2%), smoking (27.3%) and diabetes (21.9%) compared to controlled HTN patients (37.5%, 29.7%, 28.1%, 14.1% and 7.8% respectively), p<0.001. Regression analysis showed strongest association of resistant HTN with CKD (OR 6.64), stage III HTN (OR 3.07) and obesity/overweight (OR 2.60). In contrast, single-pill combinations (SPCs) were associated with lower likelihood of uncontrolled HTN (OR 0.58); Conclusions: Resistant HTN represented a small proportion of all hypertensives in our study, but it was characterized by high/very high cardiovascular risk. Optimized therapy including increased usage of SPCs could improve blood pressure control and long-term prognosis of these patients.
- 13 November 2023
- Published by Peytchinski Publishing Ltd. in Journal of IMAB – Annual Proceeding (Scientific Papers)
- Vol. 29 (4) , 5208-5213
THE PREVALENCE AND SEVERITY OF DEPRESSION AND ANXIETY IN HEART FAILURE PATIENTS IN BULGARIA
Background: Depression and anxiety are common in patients with heart failure (HF). They are associated with adverse outcomes such as reduced adherence to treatment, poor ventricular function, increased hospitalizations, and higher mortality rate. However, despite the importance of these concomitant conditions, depression and anxiety often remain underdiagnosed and undertreated in patients with HF. Aim: The aim of the study is to evaluate the prevalence and severity of depression and anxiety in patients with HF. Materials and methods: 138 patients with chronic HF, a mean age of 70.29 ± 9.73 years and male/female ratio – 63 (45.7%)/75 (54.3%) were included in this cross-sectional study. Tests for depression (Hamilton Depression Rating Scale; HAM-D) and anxiety (Hamilton Anxiety Scale; HAM-A) were performed in all participants. Results: 114 (82.6%) of the patients with HF have depression and 98 (71%) – anxiety disorder. Mild depression was found in 38 (33.3%) patients and moderate – in 49 (42.9%). Severe depression was found in 21 (18.4%) of the patients and very severe – in 6 (5.3%). In our cohort, women more often were diagnosed with depression than men (71.4% vs. 28.6%, (p<0.05)). Older age above 70 years was associated with an incidence of depression (AUC 0.75, 67% sensitivity and 64% specificity, p<0.05). Significant predictors of depression in HF patients were anemia (OR 2.74 (95% CI 1.23-4.56, p<0.05), CKD (OR 12.29 (95% CI 1.57-16.17, P<0.05), ejection fraction below 50% (OR 4.35 (95% CI 2.07-8.85, P<0.05) and alcohol consumption (OR 6.39 (95% CI 1.72 – 15.14, P<0.05). Mild anxiety was diagnosed in 28 (28.6%) of the patients, 52 (53.1%) were with moderate and 18 (18.4%) – with severe anxiety. Predictors of anxiety in our HF cohort were poor controlled arterial hypertension (OR 2,18 (95% CI 1.26-5.57 P<0.05), alcohol consumption (OR 2,75, (95% CI 1.43-4.23, P<0.05), advanced HF (OR 4.57, (95% CI 2.02-7.66, P<0.05) and previous myocardial infarction (OR 3,25, (95% CI 1.89-5.53, P<0.05). Conclusions: Out data shows that the key factors associated with the risk of developing depression in patients with HF are: CKD, anemia, alcohol use, ejection fraction < 50, while the most important factors associated with the development of anxiety are: uncontrolled hypertension, alcohol use, advanced HF and previous MI.
- 13 November 2023
- Published by Peytchinski Publishing Ltd. in Journal of IMAB – Annual Proceeding (Scientific Papers)
- Vol. 29 (4) , 5208-5213
THE PREVALENCE AND SEVERITY OF DEPRESSION AND ANXIETY IN HEART FAILURE PATIENTS IN BULGARIA
Background: Depression and anxiety are common in patients with heart failure (HF). They are associated with adverse outcomes such as reduced adherence to treatment, poor ventricular function, increased hospitalizations, and higher mortality rate. However, despite the importance of these concomitant conditions, depression and anxiety often remain underdiagnosed and undertreated in patients with HF. Aim: The aim of the study is to evaluate the prevalence and severity of depression and anxiety in patients with HF. Materials and methods: 138 patients with chronic HF, a mean age of 70.29 ± 9.73 years and male/female ratio – 63 (45.7%)/75 (54.3%) were included in this cross-sectional study. Tests for depression (Hamilton Depression Rating Scale; HAM-D) and anxiety (Hamilton Anxiety Scale; HAM-A) were performed in all participants. Results: 114 (82.6%) of the patients with HF have depression and 98 (71%) – anxiety disorder. Mild depression was found in 38 (33.3%) patients and moderate – in 49 (42.9%). Severe depression was found in 21 (18.4%) of the patients and very severe – in 6 (5.3%). In our cohort, women more often were diagnosed with depression than men (71.4% vs. 28.6%, (p<0.05)). Older age above 70 years was associated with an incidence of depression (AUC 0.75, 67% sensitivity and 64% specificity, p<0.05). Significant predictors of depression in HF patients were anemia (OR 2.74 (95% CI 1.23-4.56, p<0.05), CKD (OR 12.29 (95% CI 1.57-16.17, P<0.05), ejection fraction below 50% (OR 4.35 (95% CI 2.07-8.85, P<0.05) and alcohol consumption (OR 6.39 (95% CI 1.72 – 15.14, P<0.05). Mild anxiety was diagnosed in 28 (28.6%) of the patients, 52 (53.1%) were with moderate and 18 (18.4%) – with severe anxiety. Predictors of anxiety in our HF cohort were poor controlled arterial hypertension (OR 2,18 (95% CI 1.26-5.57 P<0.05), alcohol consumption (OR 2,75, (95% CI 1.43-4.23, P<0.05), advanced HF (OR 4.57, (95% CI 2.02-7.66, P<0.05) and previous myocardial infarction (OR 3,25, (95% CI 1.89-5.53, P<0.05). Conclusions: Out data shows that the key factors associated with the risk of developing depression in patients with HF are: CKD, anemia, alcohol use, ejection fraction < 50, while the most important factors associated with the development of anxiety are: uncontrolled hypertension, alcohol use, advanced HF and previous MI.
- Open Access
- 19 July 2023
- Published by Pensoft Publishers in Bulgarian Cardiology
- Vol. 29 (2) , 5-6
Editorial
Редакционен коментар Editorial
- 19 July 2023
- Published by Pensoft Publishers in Bulgarian Cardiology
- Vol. 29 (2) , 5-6
Open AccessEditorial
Редакционен коментар Editorial
- Open Access
Are Three Weeks of Oral Anticoagulation Sufficient for Safe Cardioversion in Atrial Fibrillation?
Background and Objectives: Patients with atrial fibrillation (AF), lasting >48 h, considered for cardioversion, are recommended ≥3 weeks of oral anticoagulation before sinus rhythm restoration because of high risk of development of left atrial thrombosis (LAT) and stroke. However, the optimal duration of anticoagulation in the presence of overt LAT is unknown. Materials and Methods: An open-label study aimed to investigate the prevalence of spontaneous echo contrast (SEC) and LAT before and after 3 weeks of direct oral anticoagulant (DOAC) treatment. We included 51 consecutive patients (50.9% males), mean age 69.3 ± 7.4 years with paroxysmal/unknown duration of AF, considered for cardioversion, who agreed to have transesophageal echocardiography at enrollment and 3 weeks later. Results: At baseline SEC was present in 26 (50.9%) and LAT in 10 (19.6%) of 51 patients. After 3 weeks on DOAC, SEC persisted in 12 (25.0%) and LAT in 7 (14.5%) of 48 patients, p < 0.05 vs. baseline. Factors, associated most strongly with persistence of SEC/LAT, were left atrial appendage (LAA) emptying velocity 2 (OR = 1.84), and indexed left atrial volume ≥34 mL/m2 (OR = 1.37). Conclusions: In our study the incidence of SEC/LAT, particularly in AF with unknown duration, was not as low as we expected. The prevalence of SEC/LAT seemed to be dependent on factors not routinely evaluated in AF patients planned for cardioversion (indexed LA volume, LAA morphology and number of lobules, LAA emptying velocity, etc.). Our data suggested an individualized approach for DOAC duration in AF patients before an attempt for restoration of sinus rhythm is made, taking into consideration the LAA morphology and function.
Open AccessAre Three Weeks of Oral Anticoagulation Sufficient for Safe Cardioversion in Atrial Fibrillation?
Background and Objectives: Patients with atrial fibrillation (AF), lasting >48 h, considered for cardioversion, are recommended ≥3 weeks of oral anticoagulation before sinus rhythm restoration because of high risk of development of left atrial thrombosis (LAT) and stroke. However, the optimal duration of anticoagulation in the presence of overt LAT is unknown. Materials and Methods: An open-label study aimed to investigate the prevalence of spontaneous echo contrast (SEC) and LAT before and after 3 weeks of direct oral anticoagulant (DOAC) treatment. We included 51 consecutive patients (50.9% males), mean age 69.3 ± 7.4 years with paroxysmal/unknown duration of AF, considered for cardioversion, who agreed to have transesophageal echocardiography at enrollment and 3 weeks later. Results: At baseline SEC was present in 26 (50.9%) and LAT in 10 (19.6%) of 51 patients. After 3 weeks on DOAC, SEC persisted in 12 (25.0%) and LAT in 7 (14.5%) of 48 patients, p < 0.05 vs. baseline. Factors, associated most strongly with persistence of SEC/LAT, were left atrial appendage (LAA) emptying velocity 2 (OR = 1.84), and indexed left atrial volume ≥34 mL/m2 (OR = 1.37). Conclusions: In our study the incidence of SEC/LAT, particularly in AF with unknown duration, was not as low as we expected. The prevalence of SEC/LAT seemed to be dependent on factors not routinely evaluated in AF patients planned for cardioversion (indexed LA volume, LAA morphology and number of lobules, LAA emptying velocity, etc.). Our data suggested an individualized approach for DOAC duration in AF patients before an attempt for restoration of sinus rhythm is made, taking into consideration the LAA morphology and function.
- Open Access
- 19 April 2021
- Published by MDPI AG in Preprints.org
Are Three Weeks of Oral Anticoagulation Sufficient for Safe Cardioversion in Atrial Fibrillation?
Background: Patients with atrial fibrillation (AF), lasting >48 h, considered for cardioversion, are recommended ≥3 weeks of oral anticoagulation before sinus rhythm restoration because of high risk of development of left atrial thrombosis (LAT) and stroke. However, the optimal duration of anticoagulation in the presence of overt LAT is unknown. Methods: An open-label study, aiming to investigate the prevalence of spontaneous echo con-trast (SEC) and LAT before and after 3 weeks of direct oral anticoagulant (DOAC) treatment. We included 51 consecutive patients (50.9% males), mean age 69.3±7.4 years with paroxys-mal/unknown duration of AF, considered for cardioversion, who agreed to have transesophage-al echocardiography at enrollment and 3 weeks later. Results: At baseline SEC was present in 26 (50.9%) and LAT in 10 (19.6%) of 51 patients. After 3 weeks on DOAC, SEC persisted in 12 (25.0%) and LAT in 7 (14.5%) of 48 patients, p<0.05 vs base-line. Factors, associated most strongly with persistence of SEC/LAT were left atrial appendage (LAA) emptying velocity 2 (OR=1.84) and indexed left atrial volume ≥34 ml/m2 (OR=1.37). Conclusions: The recommended minimal period of 3 weeks of oral anticoagulation lead to SEC/LAT resolution in 47% of our patients. To our opinion, LA/LAA morphology and function should be taken into account when determining the duration of DOAC treatment before planned cardioversion.
- 19 April 2021
- Published by MDPI AG in Preprints.org
Open AccessAre Three Weeks of Oral Anticoagulation Sufficient for Safe Cardioversion in Atrial Fibrillation?
Background: Patients with atrial fibrillation (AF), lasting >48 h, considered for cardioversion, are recommended ≥3 weeks of oral anticoagulation before sinus rhythm restoration because of high risk of development of left atrial thrombosis (LAT) and stroke. However, the optimal duration of anticoagulation in the presence of overt LAT is unknown. Methods: An open-label study, aiming to investigate the prevalence of spontaneous echo con-trast (SEC) and LAT before and after 3 weeks of direct oral anticoagulant (DOAC) treatment. We included 51 consecutive patients (50.9% males), mean age 69.3±7.4 years with paroxys-mal/unknown duration of AF, considered for cardioversion, who agreed to have transesophage-al echocardiography at enrollment and 3 weeks later. Results: At baseline SEC was present in 26 (50.9%) and LAT in 10 (19.6%) of 51 patients. After 3 weeks on DOAC, SEC persisted in 12 (25.0%) and LAT in 7 (14.5%) of 48 patients, p<0.05 vs base-line. Factors, associated most strongly with persistence of SEC/LAT were left atrial appendage (LAA) emptying velocity 2 (OR=1.84) and indexed left atrial volume ≥34 ml/m2 (OR=1.37). Conclusions: The recommended minimal period of 3 weeks of oral anticoagulation lead to SEC/LAT resolution in 47% of our patients. To our opinion, LA/LAA morphology and function should be taken into account when determining the duration of DOAC treatment before planned cardioversion.